Cited 0 times in
Incidence and Features of Lymphoid Proliferation and Lymphomas after Solid Organ or Hematopoietic Stem Cell Transplantation in a National Database Cohort
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강지만 | - |
dc.contributor.author | 안종균 | - |
dc.contributor.author | 이명지 | - |
dc.contributor.author | 인경 | - |
dc.contributor.author | 정인경 | - |
dc.contributor.author | 주동진 | - |
dc.contributor.author | 한승민 | - |
dc.date.accessioned | 2024-03-22T06:27:06Z | - |
dc.date.available | 2024-03-22T06:27:06Z | - |
dc.date.issued | 2024-01 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198554 | - |
dc.description.abstract | Purpose Post-transplantation lymphoproliferative disorders (PTLDs) after hematopoietic stem transplantation (HCT) or solid organ transplantation (SOT) result in poorer outcomes, including death. There are limited large cohort data on the incidence and natural course of PTLD in Asians.Materials and Methods We investigated PTLD using Korean national health insurance claims data of 47,518 patients who underwent HCT or SOT in 2008-2020. Patient demographics, time and type of PTLD diagnosis, type of PTLD treatment, and death data were collected. We used Fine and Gray subdistribution hazard models to calculate the cumulative incidence and risk factors for PTLD.Results During median follow-up of 5.32 years, PTLD occurred in 294 of 36,945 SOT patients (0.79%) and 235 of 10,573 HCT patients (2.22%). Cumulative incidence of PTLD were 0.49% at 1 year, 1.02% at 5 years, and 1.50% at 10 years post-transplantation. Age < 20 years (subdistribution hazard ratio [SHR] of 1.67 in age 10-19, SHR 1.51 in age 0-9), HCT (SHR 3.02), heart transplantation (SHR 2.27), and liver transplantation (SHR 1.47) were significant risk factors for PTLD. The presence of PTLD was associated with an increased risk of death (hazard ratio of 2.84). Overall, 5-year survival of PTLD patients was 68.9% (95% confidence interval, 64.9 to 73.2).Conclusion We observed a steady increase in PTLD over 10 years after HCT or SOT in this large cohort study. Pediatric age group, HCT, liver transplantation, and heart transplantation were suggested to be risk factors for PTLD, and PTLD was associated with a higher risk of death. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Cell Proliferation | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Epstein-Barr Virus Infections* / complications | - |
dc.subject.MESH | Hematopoietic Stem Cell Transplantation* / adverse effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Infant, Newborn | - |
dc.subject.MESH | Lymphoma* / epidemiology | - |
dc.subject.MESH | Lymphoma* / etiology | - |
dc.subject.MESH | Lymphoma* / therapy | - |
dc.subject.MESH | Lymphoproliferative Disorders* / diagnosis | - |
dc.subject.MESH | Lymphoproliferative Disorders* / epidemiology | - |
dc.subject.MESH | Lymphoproliferative Disorders* / etiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Young Adult | - |
dc.title | Incidence and Features of Lymphoid Proliferation and Lymphomas after Solid Organ or Hematopoietic Stem Cell Transplantation in a National Database Cohort | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학교실) | - |
dc.contributor.googleauthor | Seung Min Hahn | - |
dc.contributor.googleauthor | Myeongjee Lee | - |
dc.contributor.googleauthor | JongHoon Hyun | - |
dc.contributor.googleauthor | Sungmin Lim | - |
dc.contributor.googleauthor | Ji-Man Kang | - |
dc.contributor.googleauthor | Jong Gyun Ahn | - |
dc.contributor.googleauthor | Dong Jin Joo | - |
dc.contributor.googleauthor | Inkyung Jung | - |
dc.contributor.googleauthor | Kyong Ihn | - |
dc.identifier.doi | 10.4143/crt.2023.647 | - |
dc.contributor.localId | A05720 | - |
dc.contributor.localId | A02261 | - |
dc.contributor.localId | A05996 | - |
dc.contributor.localId | A05505 | - |
dc.contributor.localId | A03693 | - |
dc.contributor.localId | A03948 | - |
dc.contributor.localId | A04299 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 37475137 | - |
dc.subject.keyword | Hematopoietic stem cell transplantation | - |
dc.subject.keyword | Lymphoma | - |
dc.subject.keyword | Lymphoproliferative disorders | - |
dc.subject.keyword | Organ transplantation | - |
dc.contributor.alternativeName | Kang, Ji-Man | - |
dc.contributor.affiliatedAuthor | 강지만 | - |
dc.contributor.affiliatedAuthor | 안종균 | - |
dc.contributor.affiliatedAuthor | 이명지 | - |
dc.contributor.affiliatedAuthor | 인경 | - |
dc.contributor.affiliatedAuthor | 정인경 | - |
dc.contributor.affiliatedAuthor | 주동진 | - |
dc.contributor.affiliatedAuthor | 한승민 | - |
dc.citation.volume | 56 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 305 | - |
dc.citation.endPage | 313 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.56(1) : 305-313, 2024-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.